Testing glofitamab plus chemo for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and newly diagnosed with DLBCL (a type of lymphoma) without prior treatment, except for a short course of steroids or palliative radiation.
- You need at least one tumor that can be seen on a scan (at least 1.5 cm in a lymph node or 1 cm outside of it).
- Your heart function must be good, with an ejection fraction of 50% or higher on echocardiogram or MUGA scan.
- You cannot have lymphoma in the brain or spinal cord, or have had certain prior treatments like anthracycline, rituximab, or CD3 bispecific antibodies.
- You must be willing to use effective contraception during and for a period after treatment, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This study looks at how well the drug glofitamab works and how safe it is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or hasn't gotten better after treatment. It's for adults in China who are either about to start glofitamab or have started it within the past 6 months.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.